The FDA has approved infliximab-dyyb as a biosimilar and not as an interchangeable biological.
The FDA has approved Inflectra (infliximab-dyyb), administered as an intravenous infusion, for multiple indications. This is biosimilar to Janssen Biotech’s Remicade (infliximab). The approval comes just over a year after the first biosimilar product, Zarxio (filgrastim-sndz), was approved by the FDA.
The indications for this second biosimilar product in the United States include:
The approval followed an FDA review of structural and functional data, animal study data, human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data, and other clinical safety and effectiveness data of infliximab-dyyb. The review convinced the FDA that infliximab-dyyb is biosimilar to infliximab. It is important to note that infliximab-dyyb has not been approved as an interchangeable product.
Janet Woodcock, MD, director of FDA’s Center for Drug Evaluation and Research said in a statement, “Biosimilars can provide access to important treatment options for patients who need them. Patients and the health care community can be confident that biosimilar products are high quality and meet the agency’s rigorous scientific standards.”
The cost of infliximab-dyyb will of course be an important factor that could significantly impact acceptance. A single infusion of infliximab can cost anywhere between $1300 and $2500. Unless the biosimilar is sold at a significantly lower price, shifting consumer preference could be a challenge, especially since providers and patients alike have been cautious with accepting biosimilars.
Infliximab-dyyb is manufactured by Celltrion, Inc, based in the Republic of Korea, for Hospira. It will be marketed in the United States by Pfizer.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More